ESC 365 - Bleeding risk for non-valvular AF patients prescribed warfarin, or standard doses of apixaban 5mg BID, dabigatran 150mg BID or rivaroxaban 20mg QD in real-world practice: Findings from EHR

ESC Premium Access

Bleeding risk for non-valvular AF patients prescribed warfarin, or standard doses of apixaban 5mg BID, dabigatran 150mg BID or rivaroxaban 20mg QD in real-world practice: Findings from EHR

Session: Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?

Topic: Atrial fibrillation (AF)

Speaker: Professor G. Lip (Liverpool, GB)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Gregory Yh Lip

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)

100 presentations

9 followers

4 more presentations in this session

State of the art in bleeding risk in atrial fibrillation.

Speaker: Professor I. Van Gelder (Groningen, NL)

Factors associated with quality of anticoagulation control in patients with atrial fibrillation and risk of stroke and bleeding

Speaker: Mr A. Nissen Bonde (Gentofte, DK)

Major bleeding among patients with atrial fibrillation treated with rivaroxaban or warfarin in Sweden. Interim results from an on-going post-authorization study

Speaker: Associate Professor L. Friberg (Stockholm, SE)

Future direction for research in antithrombotic therapy in atrial fibrillation.

Speaker: Professor E. Hylek (Boston, US)

Access the full session

Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?

Speakers: Professor G. Lip, Professor I. Van Gelder, Mr A. Nissen Bonde, Associate Professor L. Friberg, Professor E. Hylek

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources